Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine 4 weeks post-vaccination 3 (Month 7) [clinicaltrials_resource:a83f03c081e0e05fc3b2d37e40f629b2]
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine 4 weeks post-vaccination 3 (Month 7) [clinicaltrials_resource:a83f03c081e0e05fc3b2d37e40f629b2]
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Bio2RDF identifier
a83f03c081e0e05fc3b2d37e40f629b2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a83f03c081e0e05fc3b2d37e40f629b2
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants Who ...... Types Contained in the Vaccine
time frame [clinicaltrials_vocabulary:time-frame]
4 weeks post-vaccination 3 (Month 7)
description
Serum antibody titers for HPV ...... e 52: ≥8, and HPV Type 58: ≥8.
identifier
clinicaltrials_resource:a83f03c081e0e05fc3b2d37e40f629b2
title
Percentage of Participants Who ...... s post-vaccination 3 (Month 7)
@en
type
label
Percentage of Participants Who ...... f03c081e0e05fc3b2d37e40f629b2]
@en